Peroxisome proliferator-activated receptors-y and hypertension: Lessons of the history of researches

Terapevticheskii Arkhiv

Volumn 85, Issue 9, 2013, Pages 118-123

  Rasin, M S ^a  

^a UKRAINIAN MEDICAL STOMATOLOGICAL ACADEMY   (Ukraine)

Author keywords

Hypertension; Peroxisome proliferator activated receptors y; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

GENETICS; HUMAN; HYPERTENSION; METABOLISM; REVIEW;

HUMANS; HYPERTENSION; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84889599362     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Issemanrt I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Proc Natl Acad Sci USA 1999; 47: 645-650.
2. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
3. Lehmann J.M., Moore L.B., Smith-Oliver T.A. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953-12956.
4. Getz G.S. Bridging the innate and adaptive immune systems. J Lipid Res 2005; 46:619-627.
5. Barroso I., Gurnell M., Crowley V.E.F. et al. Dominant negative mutations in human PPAR are associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
6. Pascual G., Fong A. L., Ogawa S. et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Proc Natl Acad Sci USA 2005; 402: 880-883.
7. Gurnell M., David B., Savage E. et al. PPAR ligand resistance (PLR) syndrome. The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor and Its Therapeutic Modulation. J Clin Endocrinol Metab 2003; 88: 2412-2421.
8. Fonseca KA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 2003; 18: 50J-60J.
9. Reaven G.M. Relationships Among Insulin Resistance, Type 2 Diabetes, Essential Hypertension, and Cardiovascular Disease: Similarities and Differences. J Clin Hypertens 2011; 13:238-243.
10. Desvergne B., Michalik L., Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004; 18 (6): 1321-1332.
11. Grundy S.M. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003; 290: 3000-3002.
12. Agostini M., Gurnell M., Savage D.B. et al. Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant- Negative Mutations in Human Peroxisome Proliferator-Activated Receptor. Endocrinology 2004; 145:1527-1538.
13. Agarwal A.K., Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy J Clin Endocrinol Metab 2002; 87:408-411.
14. Stefanskl A., MajkowskalL, Ciechanowicz A. et al. Association between the Prol2Aia variant of the peroxisome proliferator- Activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obeshe patients with type II diabetes. J Hum Hypertens 2006; 20; 684-692.
15. Potenza M.A., Gagliardi S., De Benedictis A. et al. Endocrinol Metab 2009; 297: E685-E694.
16. Tsai Y.S., Kim H.J., Takahashi N. et al. J Clin Invest 2009; 114: 240-249.
17. Beyer A.M. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 2008; 51:867-871.
18. Kleinhenz J.M., Kleinhenz D.J., You S. et al. Am J Physiol Heart Circ Physiol 2009; 297: H1647-H1654.
19. Chang L., Villacorta L., Zhanget J. et al. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation 2009; 119: 2161- 2169.
20. Reaven G.M., Lithell H.f Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374-381.
21. Steinberg H.O., Brechtel G., Johnson A. et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Investigat 1994; 94 (3): 1172-1179.
22. Robitaille J., Despres J.P., Perusse L., Vohl M.C. The PPAR-gamma PI 2A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet 2003; 63:109-116.
23. Schlaich M.P., Lambert E., Kaye D.M. et al. Sympathetic nervous augmentation in essential hypertension: role of nerve firing, norepinephrine reuptake and angiotensin neuromodulation. Hypertension 2004; 43: 169-175.
24. Ester M.D., Krum H., Sobotka P.A. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomized controlled trial. Lancet 2010; 376:1903-1909.
25. Festa A., D'Agostino Jr R., Howard G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
26. Aizawa-Abe M., Ogawa Y., Masuiaki H. et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2010; 105: 1243-1252.
27. Bataineh A., Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl 1998; 68: SI4-S19.
28. Sesso H.D., Buring J.E., Rifai N. et al. C-reactive protein and the risk of developing ypertension. JAMA 2003; 290: 2945-2951.
29. Li J., Doerffel Y., Hocher C.B. Inflammation in the genesis of hypertension and its complications-the role of angiotensin II. Nephrol Dialys Transplantat 2007; 22 (11): 3107-3109.
30. Christopher B.J., Gregory Y.H. Is Hypertension an Inflammatory Process? Cur Pharmaceut Design 2006; 12:1623-1635.
31. Cheng Z.J., Vapaatalo H., Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: RA194-RA205.
32. Pauletto P., Ratlazzi M. Inflammation and hypertension: The search for a link. Nephrol Dial Transplant 2006; 21: 850-853.
33. Endemann D.H., Schiffrin E.L. Endothelial Dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992.
34. Licastro E, Candore G., Domenico Lio et al. Innate immunity and inflammation in ageing: A key for understanding age-related diseases. Immun Ageing 2005; 2: 8-17.
35. Lonn E.M., Gerstein H.C., Sheridan P. et al. Diabetes reduction assessment with ramipril and rosiglitazone medication. J Am Coll Cardiol 2009; 53: 2028-2035.
36. Ricote M., Valledor A.F., Glass C.K. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vase Biol 2004; 24: 230-239.
37. Clarke D.L., PateI H.J., Mitchell J.A. Regulation of the release of colony-stimulating factors from human airway smooth muscle cells by prostaglandin E2. Br J Pharmacol 2001; 133:40-45.
38. Al-Shali K.Z., House A.A., Hanley J.G. et al. Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor {gamma} Associated With Carotid Atherosclerosis. Stroke 2004; 35 (9): 2036-2040.
39. Nie M., Corbett L., Knox A. J., Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: Interactions with glucocorticoids and beta 2-agonists. Biol Chem 2004; 324:47-50.